Paper3910216
Carboplatin as a potentiator of radiation therapy.
Douple EB and 3 others. Cancer Treat Rev, 1985. Cited by 159 papers, by iCite.
Cite this record
ConductScience Library. Carboplatin as a potentiator of radiation therapy. Papers, record 3910216. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/3910216
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents | Major topic |
| Neoplasms | Major topic |
| Organoplatinum Compounds | Major topic |
| Radiation-Sensitizing Agents | Major topic |
| Animals | |
| Carboplatin | |
| Combined Modality Therapy | |
| Cricetinae | |
| Cricetulus | |
| Humans | |
| Mice | |
| Platinum |
Source PubMed
Cited by22
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 159 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41059462 | Osteosarcoma of the appendicular skeleton in dogs: consensus and guidelines. | Front Vet Sci | 2025 | https://conductscience.org/library/papers/41059462 | PubMed |
| 40283954 | Mechanisms of Action of AGuIX as a Pan-Cancer Nano-Radiosensitizer: A Comprehensive Review. | Pharmaceuticals (Basel) | 2025 | https://conductscience.org/library/papers/40283954 | PubMed |
| 31196855 | Loss of ARID1A in Tumor Cells Renders Selective Vulnerability to Combined Ionizing Radiation and PARP Inhibitor Therapy. | Clin Cancer Res | 2019 | https://conductscience.org/library/papers/31196855 | PubMed |
| 30332335 | Extensive Molecular and Clinical Heterogeneity in Patients With Histologically Diagnosed CNS-PNET Treated as a Single Entity: A Report From the Children's Oncology Group Randomized ACNS0332 Trial. | J Clin Oncol | 2018 | https://conductscience.org/library/papers/30332335 | PubMed |
| 29761244 | Copper-tolfenamic acid: evaluation of stability and anti-cancer activity. | Invest New Drugs | 2019 | https://conductscience.org/library/papers/29761244 | PubMed |
| 29386671 | Metronomic administration of lomustine following palliative radiation therapy for appendicular osteosarcoma in dogs. | Can Vet J | 2018 | https://conductscience.org/library/papers/29386671 | PubMed |
| 27574453 | Comparison of the short-term efficacy between docetaxel plus carboplatin and 5-fluorouracil plus carboplatin in locoregionally advanced nasopharyngeal carcinoma. | Onco Targets Ther | 2016 | https://conductscience.org/library/papers/27574453 | PubMed |
| 26029027 | Efficacy of intensity-modulated radiotherapy with concurrent carboplatin in nasopharyngeal carcinoma. | Radiol Oncol | 2015 | https://conductscience.org/library/papers/26029027 | PubMed |
| 25755911 | Concomitant use of radiotherapy and two topoisomerase inhibitors to treat adult T-cell leukemia with a radiotherapy-resistant bulky disease: a case series. | Am J Blood Res | 2014 | https://conductscience.org/library/papers/25755911 | PubMed |
| 25493083 | The long-term outcomes of induction chemoradiotherapy followed by surgery for locally advanced non-small cell lung cancer. | Case Rep Oncol | 2014 | https://conductscience.org/library/papers/25493083 | PubMed |
| 24772308 | Phase II study of concurrent chemoradiotherapy with carboplatin and vinorelbine for locally advanced non-small-cell lung cancer. | Mol Clin Oncol | 2014 | https://conductscience.org/library/papers/24772308 | PubMed |
| 24234333 | Feasibility and safety of carboplatin plus paclitaxel as neoadjuvant chemotherapy for locally advanced cervical cancer: a pilot study. | Tumour Biol | 2014 | https://conductscience.org/library/papers/24234333 | PubMed |
| 23292146 | Phase I study of oral S-1 and concurrent radiotherapy in patients with head and neck cancer. | J Radiat Res | 2013 | https://conductscience.org/library/papers/23292146 | PubMed |
| 20514254 | Clinical outcome in dogs with nasal tumors treated with intensity-modulated radiation therapy. | Can Vet J | 2010 | https://conductscience.org/library/papers/20514254 | PubMed |
| 20205484 | Pharmacotherapy options for locally advanced and advanced cervical cancer. | Drugs | 2010 | https://conductscience.org/library/papers/20205484 | PubMed |
| 19219603 | Analysis of feasibility and toxicity of concurrent chemoradiotherapy with S-1 for locally advanced squamous cell carcinoma of the head and neck in elderly cases and/or cases with comorbidity. | Cancer Chemother Pharmacol | 2009 | https://conductscience.org/library/papers/19219603 | PubMed |
| 16722549 | Radiosensitizers in cervical cancer. Cisplatin and beyond. | Radiat Oncol | 2006 | https://conductscience.org/library/papers/16722549 | PubMed |
| 15299181 | Concomitant radiochemotherapy vs radiotherapy alone in patients with head and neck cancer: a Hellenic Cooperative Oncology Group Phase III Study. | Med Oncol | 2004 | https://conductscience.org/library/papers/15299181 | PubMed |
| 12177791 | Dose-escalation study of weekly irinotecan and daily carboplatin with concurrent thoracic radiotherapy for unresectable stage III non-small cell lung cancer. | Br J Cancer | 2002 | https://conductscience.org/library/papers/12177791 | PubMed |
| 8519652 | Carboplatin- and cisplatin-induced potentiation of moderate-dose radiation cytotoxicity in human lung cancer cell lines. | Br J Cancer | 1995 | https://conductscience.org/library/papers/8519652 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/3910216
GET https://conductscience.org/api/papers/v1/3910216/cited_by?page=2